TCRX Q4 2021 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+259.0% YoY

Gross Profit

-$10M-341.8% margin

Operating Income

-$14M-497.6% margin

Net Income

-$14M-497.5% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+18.3%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$17M

Stock-Based Comp.

$784,000

Balance Sheet

Total Assets

$188M

Total Liabilities

$27M

Stockholders' Equity

$161M

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$795,000	+259.0%
Gross Profit	-$10M	-$5M	-88.7%
Operating Income	-$14M	-$8M	-81.8%
Net Income	-$14M	-$8M	-81.9%